| References: |
Pyridoclax is able to disrupt BimL/Mcl-1 interaction in whole living cells. Pyridoclax strongly sensitizes ovarian cancer chemoresistant IGROV1-R10 cells to Bcl-xL targeting siRNA, their combination leading to massive apoptosis. Neither ABT-737 nor Pyridoclax induced cell death as single agents, whereas their combination led to massive apoptotic cell death in both IGROV1-R10 and SKOV3 chemoresistant ovarian cancer cell lines. For the detailed information of Pyridoclax(MR29072), the solubility of Pyridoclax(MR29072) in water, the solubility of Pyridoclax(MR29072) in DMSO, the solubility of Pyridoclax(MR29072) in PBS buffer, the animal experiment (test) of Pyridoclax(MR29072), the cell expriment (test) of Pyridoclax(MR29072), the in vivo, in vitro and clinical trial test of Pyridoclax(MR29072), the EC50, IC50,and affinity,of Pyridoclax(MR29072), For the detailed information of Pyridoclax(MR29072), the solubility of Pyridoclax(MR29072) in water, the solubility of Pyridoclax(MR29072) in DMSO, the solubility of Pyridoclax(MR29072) in PBS buffer, the animal experiment (test) of Pyridoclax(MR29072), the cell expriment (test) of Pyridoclax(MR29072), the in vivo, in vitro and clinical trial test of Pyridoclax(MR29072), the EC50, IC50,and affinity,of Pyridoclax(MR29072), Please contact DC Chemicals. |
.gif)
